AN
Anuh Pharma Ltd (ANUHPHR)
₹85.85
Mkt cap
₹937 Cr
P/E ratio
21.20
P/B
2.45
Div yield
1.60%
ROE
10.70%
ROCE
14.90%
EPS (TTM)
₹4.05
Book value
₹35
52W range
67–100
Sector
Healthcare
Price history
Previous close
Incorporated in 1960, Anuh Pharma Ltd is in the business of manufacturing and selling of Bulk drugs and chemicals [1]
NSE ANUHPHRBSE 506260
Health check
Constructive
ValuationCheap
ProfitabilityAverage
GrowthModerate
TechnicalsBullish
52-week range
−13.72% from high₹86
₹67+28.13% from low₹100
Current
₹85.85
Prev close
₹87.40
Day
−1.77%
Price performance
1D
−2.16%
1W
−5.81%
1M
+5.01%
3M
+6.29%
6M
+27.63%
1Y
+0.16%
YTD
+7.04%
Financials
Revenue, profit & margin
P/E ratio
21.2×
ANUHPHR is 39% below the sector median of 34.6×
ANUHPHR21.2×
Sector median34.6×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 161 | 150 | 172 | 164 | 138 | 166 | 160 | 198 | 186 | 186 | 197 | 202 | 194 | |
| Expenses | 148 | 132 | 148 | 145 | 127 | 149 | 145 | 179 | 176 | 174 | 178 | 182 | 178 | |
| Operating Profit | 14 | 18 | 24 | 19 | 11 | 17 | 15 | 19 | 10 | 12 | 19 | 20 | 16 | |
| OPM % | 9% | 12% | 14% | 12% | 8% | 10% | 9% | 9% | 6% | 6% | 10% | 10% | 8% | |
| Other Income | 3 | 2 | 4 | 3 | 4 | 3 | 1 | 1 | 3 | 1 | 2 | -1 | 3 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 2 | |
| Profit before tax | 15 | 18 | 25 | 20 | 12 | 18 | 13 | 17 | 11 | 10 | 18 | 16 | 17 | |
| Tax % | 24% | 23% | 24% | 22% | 22% | 17% | 22% | 28% | 24% | 23% | 25% | 25% | 32% | |
| Net Profit | 12 | 14 | 19 | 15 | 10 | 15 | 10 | 12 | 8 | 8 | 13 | 12 | 11 | |
| EPS in Rs | 1.17 | 1.38 | 1.91 | 1.53 | 0.95 | 1.50 | 1.03 | 1.24 | 0.83 | 0.76 | 1.34 | 1.17 | 1.14 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −2.12% · closed higher next day 0 of last 1
| Q1FY27† | |
|---|---|
| Broadcast | 7 Aug '26◦ |
| Earnings day | −2.12% |
| +1 day | −1.97% |
| +5 days | −4.54% |
| +15 days | +3.43% |
| +30 days | +17.85% |
| Filing |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Jun 202671.79%Promoter
Promoters71.79%
FIIs0.01%0.04
DIIs0.00%
Public28.19%0.05
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Anuh Pharma | ₹93.48 | 21.22 | 937 | 1.60% | 11 | +37.59% | 194 | +3.93% | 14.94% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports15
Concall transcripts34
Credit ratings6
Announcements5
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 (''''SEBI LODR'''') 18 Sep - Income tax demand order of Rs 9,93,206 for AY 2018-19; company will appeal.Announcement under Regulation 30 (LODR)-Investor Presentation 19 AugAnnouncement Under Regulation 30 - General Updates 14 Aug - 66th AGM on 12 Aug 2026 approved director reappointments, cost auditor reappointment, JMD pay revisions, new MOA/AOA.Announcement under Regulation 30 (LODR)-Change in Management 14 Aug - At 66th AGM on 12 Aug 2026, shareholders approved director reappointments, cost auditor reappointment, and JMD remuneration revisions.Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 14 Aug - 66th AGM voting results approved; Rs.1.50 dividend, director reappointments, remuneration revisions, and MoA/AoA changes passed.